iData Insights

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Jan 23, 2016 14:23 IST

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015 Summary Global Markets Direct s, Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015, provides an overview of the Cytomegalovirus (HHV-5) Infectionss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cytomegalovirus (HHV-5) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173359/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=173359/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015

Table of Contents

Introduction 8

Global Markets Direct Report Coverage 8

Cytomegalovirus (HHV-5) Infections Overview 9

Therapeutics Development 10

Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 10

Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 11

Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 12

Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 15

Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 20

Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 23

Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 24

AIMM Therapeutics B.V. 24

Altor BioScience Corporation 25

Applied Immune Technologies Ltd 26

Astellas Pharma Inc. 27

Atara Biotherapeutics, Inc. 28

Bionor Pharma ASA 29

Biotest AG 30

CAP-CMV GmbH 31

Cell Medica Limited 32

Chimerix, Inc. 33

China Biologic Products, Inc. 34

CyTuVax B.V. 35

GlaxoSmithKline Plc 36

Hookipa Biotech AG 37

Humabs BioMed SA 38

iQur Limited 39

Kadmon Corporation, LLC 40

Lead Discovery Center GmbH 41

Merck & Co., Inc. 42

Microbiotix, Inc. 43

Novartis AG 44

Pfizer Inc. 45

Phoenix Biotechnology, Inc. 46

Savoy Pharmaceuticals, Inc. 47

Trellis Bioscience, Inc. 48

Vakzine Projekt Management GmbH 49

VBI Vaccines Inc. 50

Vical Incorporated 51

Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 52

Assessment by Monotherapy Products 52

Assessment by Combination Products 53

Assessment by Target 54

Assessment by Mechanism of Action 56

Assessment by Route of Administration 58

Assessment by Molecule Type 60

Drug Profiles 62

AL-18 - Drug Profile 62

Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile 63

Antibody for Human Cytomegalovirus Infection - Drug Profile 64

Antiviral TCR-Ck - Drug Profile 65

Antiviral TCR-Ig - Drug Profile 66

ASP-0113 - Drug Profile 67

brincidofovir - Drug Profile 69

BT-084 - Drug Profile 72

CAPCMV-001 - Drug Profile 73

Cell Therapy 3 For CMV - Drug Profile 74

Cell Therapy for CMV Infections - Drug Profile 75

Cell Therapy for Cytomegalovirus (HHV-5) Infections - Drug Profile 76

Cell Therapy for Cytomegalovirus Infections - Drug Profile 77

Cell Therapy for Cytomegalovirus Infections - Drug Profile 78

Cell Therapy for Cytomegalovirus Infections and GBM - Drug Profile 79

Cell Therapy for Infectious Disease - Drug Profile 80

Cell Therapy for Infectious Diseases - Drug Profile 81

Cell Therapy for Viral Infections Post-HSCT - Drug Profile 82

Cell Therapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 83

Cell Therapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 85

Cellular Immunotherapy for Viral Infections - Drug Profile 86

CMX-669 - Drug Profile 87

CSJ-148 - Drug Profile 88

CyMVectin - Drug Profile 89

Cytomegalovirus (virus like particles) vaccine - Drug Profile 90

Cytomegalovirus vaccine - Drug Profile 91

Cytomegalovirus vaccine - Drug Profile 92

Cytomegalovirus vaccine - Drug Profile 93

Cytomegalovirus vaccine - Drug Profile 94

Cytomegalovirus vaccine 1 - Drug Profile 95

Cytomegalovirus vaccine 2 - Drug Profile 97

Cytovir-CMV - Drug Profile 98

Dendritic Cell Therapyto Target CMV Antigen for Cytomegalovirus Infections - Drug Profile 100

Drug for Cytomegalovirus - Drug Profile 101

filociclovir - Drug Profile 102

Gene Therapy for Cytomegalovirus Infections - Drug Profile 104

HB-101 - Drug Profile 105

LDC-4297 - Drug Profile 106

letermovir - Drug Profile 107

maribavir - Drug Profile 108

MBX-2168 - Drug Profile 110

Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile 111

Monoclonal Antibody for HCMV Infections - Drug Profile 112

Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile 113

RBT-301 - Drug Profile 114

Recombinant Peptide for Infectious Diseases - Drug Profile 115

RKP-00156 - Drug Profile 116

Small Molecule 1 for Human Cytomegalovirus Infection - Drug Profile 117

Small Molecule 2 for Human Cytomegalovirus Infection - Drug Profile 118

Small Molecule 3 for Human Cytomegalovirus Infection - Drug Profile 119

Small Molecules for CMV Infections - Drug Profile 120

Small Molecules for Viral Infections - Drug Profile 121

Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 122

Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 123

Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile 124

Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections - Drug Profile 125

TRL-345 - Drug Profile 126

V-160 - Drug Profile 127

Vacc-CMV - Drug Profile 128

Vaccine for Cytomegalovirus Infection and Glioblastoma Multiforme - Drug Profile 129

VBI-1501A - Drug Profile 130

Viralym-C - Drug Profile 131

Viroprev - Drug Profile 132

VPM-2001 - Drug Profile 133

Cytomegalovirus (HHV-5) Infections - Recent Pipeline Updates 134

Cytomegalovirus (HHV-5) Infections - Dormant Projects 154

Cytomegalovirus (HHV-5) Infections - Discontinued Products 158

Cytomegalovirus (HHV-5) Infections - Product Development Milestones 159

Featured News & Press Releases 159

Appendix 168

Methodology 168

Coverage 168

Secondary Research 168

Primary Research 168

Expert Panel Validation 168

Contact Us 168

Disclaimer 169

Read More http://www.idatainsights.com/reports-landing-page.php?id=173359/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects